^
Association details:
| Biomarker: | SPI1 overexpression |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | azacitidine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PU.1 and JDP2 expression in myelodysplastic syndromes to predict treatment response and leukemia transformation.
Published date:
05/16/2018
Excerpt:
In this study we investigated PU.1 and JDP2 expression during different stages of MDS progression/AML evolution and in patients responding to Azacitidine….we demonstrated a significant upregulation in PU.1 and JDP2 expression in patients achieving a response to Azacitidine, suggesting PU.1/JDP2 could be targets of this drug.
DOI:
10.1200/JCO.2018.36.15_suppl.7065
